Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations

Emmanuel S. Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, Harsimar Kaur, Eugene Shenderov, Drew M. Pardoll, Tamara L. Lotan

Research output: Contribution to journalArticlepeer-review

Abstract

Despite aggressive clinicopathological features, mismatch repair (MMR)-mutated advanced prostate cancers are exquisitely responsive to standard and next-generation hormonal therapies, and also demonstrate anecdotal sensitivity to PD-1 inhibitors. Moreover, the presence of certain histological features (Gleason sum 9 or 10, and intraductal carcinoma) should prompt genomic evaluation of MMR deficiency, which is an actionable finding given the Food and Drug Administration's approval of pembrolizumab in this context.

Original languageEnglish (US)
Pages (from-to)378-382
Number of pages5
JournalEuropean Urology
Volume75
Issue number3
DOIs
StatePublished - Mar 2019

Keywords

  • MSH2
  • MSH6
  • Microsatellite instability
  • Mismatch repair
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations'. Together they form a unique fingerprint.

Cite this